Rituximab for the first-line treatment of chronic lymphocytic leukaemia

  • Technology appraisal guidance
  • TA174
  • Published: 
Download guidance (PDF)

Update information

Minor changes since publication

February 2014: The implementation section was updated to clarify that rituximab is recommended as an option for treating chronic lymphocytic leukaemia.

ISBN: 978-1-4731-5630-2